Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics


Vertex Pharmaceuticals Incorporated (VRTX)

Today's Latest Price: $288.38 USD

6.73 (-2.28%)

Updated Jul 16 10:21am

Add VRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

VRTX Stock Summary

  • Vertex Pharmaceuticals Inc's market capitalization of $76,515,149,593 is ahead of 97.71% of US-listed equities.
  • VRTX's price/sales ratio is 15.88; that's higher than the P/S ratio of 91.35% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Vertex Pharmaceuticals Inc is reporting a growth rate of 132.33%; that's higher than 91.05% of US stocks.
  • Stocks that are quantitatively similar to VRTX, based on their financial statements, market capitalization, and price volatility, are AMD, AMAT, MU, REGN, and NTES.
  • VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to www.vrtx.com.
VRTX Daily Price Range
VRTX 52-Week Price Range

VRTX Stock Price Chart Technical Analysis Charts


VRTX Price/Volume Stats

Current price $288.38 52-week high $306.08
Prev. close $295.11 52-week low $165.23
Day low $286.86 Volume 162,197
Day high $293.33 Avg. volume 1,907,711
50-day MA $282.45 Dividend yield N/A
200-day MA $237.35 Market Cap 74.77B

Vertex Pharmaceuticals Incorporated (VRTX) Company Bio


Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.

VRTX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$288.38$41312.1914405%

Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF model suggests the stock is undervalued by 14475.67%; returns of such proportions should be viewed with some skepticism, though. In terms of the factors that were most noteworthy in this DCF analysis for VRTX, they are:

  • The compound growth rate in the free cash flow of Vertex Pharmaceuticals Inc over the past 3.5 years is 2.66%; that's better than 93.09% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 4.58% of the free cash flow producing stocks we're observing.
  • VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 58.73% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%14120%
1%14262%
2%14405%
3%14547%
4%14689%
5%14831%

OMI, NVCR, USNU, ANIP, and CORT can be thought of as valuation peers to VRTX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


VRTX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

VRTX Latest Social Stream


Loading social stream, please wait...

View Full VRTX Social Stream

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $295.11 in the latest trading session, marking a +0.44% move from the prior day.

Yahoo | July 15, 2020

3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again

You might have noticed that the stock market doesn't seem phased much by the flurry of bad news lately. A smart strategy is to invest in stocks of companies built to survive and thrive over the long run. Here are three absolutely rock-solid stocks to buy before the next stock market crash.

Yahoo | July 12, 2020

Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $295.40, moving -0.18% from the previous trading session.

Yahoo | July 9, 2020

The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma...

Benzinga | July 8, 2020

Here's Why CRISPR Therapeutics Shares Jumped 13.8% in June

What happened Shares of CRISPR Therapeutics (NASDAQ: CRSP) jumped 13.8% in June, according to data provided by S&P Global Market Intelligence, after the biotech released data at two different medical meetings during the month.

Yahoo | July 8, 2020

Read More 'VRTX' Stories Here

VRTX Price Returns

1-mo 5.34%
3-mo 6.63%
6-mo 22.28%
1-year 62.80%
3-year 123.19%
5-year 114.94%
YTD 31.71%
2019 32.13%
2018 10.58%
2017 103.42%
2016 -41.45%
2015 5.92%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9008 seconds.